Lyell Immunopharma, Inc.

LYEL · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Assets
Cash & Equivalents$105,597$145,647$123,554$293,828
Short-Term Investments$264,930$400,576$516,598$320,966
Receivables$0$0$0$0
Inventory$0$0$0$0
Other Curr. Assets$9,067$8,463$11,143$11,492
Total Curr. Assets$379,594$554,686$651,295$626,286
Property Plant & Equip (Net)$72,939$142,317$166,265$166,639
Goodwill$0$0$0$0
Intangibles$0$0$0$0
Long-Term Investments$32,014$48,507$115,041$330,532
Tax Assets$0$0$0$0
Other NC Assets$6,312$4,519$4,960$3,949
Total NC Assets$111,265$195,343$286,266$501,120
Other Assets$0$0$0$0
Total Assets$490,859$750,029$937,561$1,127,406
Liabilities
Payables$5,366$4,817$3,917$3,207
Short-Term Debt$7,974$6,273$4,534$1,169
Tax Payable$0$0$0$0
Deferred Revenue$0$0$0$4,988
Other Curr. Liab.$40,448$23,429$28,577$37,374
Total Curr. Liab.$53,788$34,519$37,028$46,738
LT Debt$50,994$56,894$63,168$66,650
Deferred Rev, NC$0$0$0$79,665
Deferred Tax Liab, NC$0$0$0$0
Other NC Liab.$3,253$3,664$4,113$4,566
Total NC Liab.$54,247$60,558$67,281$150,881
Other Liabilities$0$0$0$0
Cap. Leases$58,968$63,167$67,702$67,819
Total Liabilities$108,035$95,077$104,309$197,619
Equity
Pref Stock$0$0$0$0
Common Stock$29$25$25$24
Retained Earnings-$1,345,106-$1,002,112-$767,480-$584,362
AOCI$291-$94-$7,599-$1,623
Other Equity$1,727,610$1,657,133$1,608,306$1,515,748
Total Equity$382,824$654,952$833,252$929,787
Supplemental Information
Minority Interest$0$0$0$0
Total Liab. & Tot. Equity$490,859$750,029$937,561$1,127,406
Net Debt-$46,629-$82,480-$55,852-$226,009
Lyell Immunopharma, Inc. (LYEL) Financial Statements & Key Stats | AlphaPilot